請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60965
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學 | |
dc.contributor.author | Pei-Yu Huang | en |
dc.contributor.author | 黃珮瑜 | zh_TW |
dc.date.accessioned | 2021-06-16T10:38:50Z | - |
dc.date.available | 2018-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-13 | |
dc.identifier.citation | 1. Yokota, J. (2000) Tumor progression and metastasis. Carcinogenesis, 21, 497-503.
2. Sheng, S., Qiao, M. and Pardee, A.B. (2009) Metastasis and AKT activation. Journal of cellular physiology, 218, 451-454. 3. Sharma, S.V. and Settleman, J. (2009) ErbBs in lung cancer. Experimental cell research, 315, 557-571. 4. Hammerschmidt, S. and Wirtz, H. (2009) Lung cancer: current diagnosis and treatment. Deutsches Arzteblatt international, 106, 809-818; quiz 819-820. 5. Feldman, B.J. and Feldman, D. (2001) The development of androgen-independent prostate cancer. Nature reviews. Cancer, 1, 34-45. 6. Garnick, M.B. (1993) Prostate-Cancer - Screening, Diagnosis, and Management. Annals of internal medicine, 118, 804-818. 7. Huggins, C. (1967) Endocrine-induced regression of cancers. Cancer Res, 27, 1925-1930. 8. Kasper, S. and Cookson, M.S. (2006) Mechanisms leading to the development of hormone-resistant prostate cancer. The Urologic clinics of North America, 33, 201-210, vii. 9. Palmberg, C., Koivisto, P., Visakorpi, T. and Tammela, T.L. (1999) PSA decline is an independent prognostic marker in hormonally treated prostate cancer. European urology, 36, 191-196. 10. Denmeade, S.R. and Isaacs, J.T. (2002) A history of prostate cancer treatment. Nature reviews. Cancer, 2, 389-396. 11. Weigelt, B., Peterse, J.L. and van 't Veer, L.J. (2005) Breast cancer metastasis: markers and models. Nature reviews. Cancer, 5, 591-602. 12. Bauer, K.R., Brown, M., Cress, R.D., Parise, C.A. and Caggiano, V. (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109, 1721-1728. 13. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A. et al. (2000) Molecular portraits of human breast tumours. Nature, 406, 747-752. 14. Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S. et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100, 8418-8423. 15. Kerr, D. (2003) Clinical development of gene therapy for colorectal cancer. Nature reviews. Cancer, 3, 615-622. 16. Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M. et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041-1047. 17. Simpson, E.L., Law, S.V. and Storrs, F.J. (2004) Prevalence of botanical extract allergy in patients with contact dermatitis. Dermatitis : contact, atopic, occupational, drug : official journal of the American Contact Dermatitis Society, North American Contact Dermatitis Group, 15, 67-72. 18. Hayashi, K., Kamiya, M. and Hayashi, T. (1995) Virucidal Effects of the Steam Distillate from Houttuynia-Cordata and Its Components on Hsv-1, Influenza-Virus, and Hiv. Planta medica, 61, 237-241. 19. Chiang, L.C., Chang, J.S., Chen, C.C., Ng, L.T. and Lin, C.C. (2003) Anti-herpes simplex virus activity of Bidens pilosa and Houttuynia cordata. Am J Chinese Med, 31, 355-362. 20. Geissberger, P. and Sequin, U. (1991) Constituents of Bidens-Pilosa L - Do the Components Found So Far Explain the Use of This Plant in Traditional Medicine. Acta Trop, 48, 251-261. 21. Rabe, T. and vanStaden, J. (1997) Antibacterial activity of South African plants used for medicinal purposes. Journal of ethnopharmacology, 56, 81-87. 22. Lu, H.M., Wu, X.J., Liang, Y.Z. and Zhang, J. (2006) Variation in chemical composition and antibacterial activities of essential oils from two species of Houttuynia THUNB. Chemical & pharmaceutical bulletin, 54, 936-940. 23. Li, G.Z., Chai, O.H., Lee, M.S., Han, E.H., Kim, H.T. and Song, C.H. (2005) Inhibitory effects of Houttuynia cordata water extracts on anaphylactic reaction and mast cell activation. Biological & pharmaceutical bulletin, 28, 1864-1868. 24. Park, E., Kum, S., Wang, C., Park, S.Y., Kim, B.S. and Schuller-Levis, G. (2005) Anti-inflammatory activity of herbal medicines: Inhibition of nitric oxide production and tumor necrosis factor-alpha secretion in an activated macrophage-like cell line. Am J Chinese Med, 33, 415-424. 25. Kim, I.S., Kim, J.H., Kim, J.S., Yun, C.Y., Kim, D.H. and Lee, J.S. (2007) The inhibitory effect of Houttuynia cordata extract on stem cell factor-induced HMC-1 cell migration. Journal of ethnopharmacology, 112, 90-95. 26. Lee, J.S., Kim, I.S., Kim, J.H., Kim, J.S., Kim, D.H. and Yun, C.Y. (2008) Suppressive effects of Houttuynia cordata Thunb (Saururaceae) extract on Th2 immune response. Journal of ethnopharmacology, 117, 34-40. 27. Han, E.H., Park, J.H., Kim, J.Y. and Jeong, H.G. (2009) Houttuynia cordata water extract suppresses anaphylactic reaction and IgE-mediated allergic response by inhibiting multiple steps of Fc epsilon RI signaling in mast cells. Food and Chemical Toxicology, 47, 1659-1666. 28. Kusirisin, W., Srichairatanakool, S., Lerttrakarnnon, P., Lailerd, N., Suttajit, M., Jaikang, C. and Chaiyasut, C. (2009) Antioxidative Activity, Polyphenolic Content and Anti-Glycation Effect of Some Thai Medicinal Plants Traditionally Used in Diabetic Patients. Med Chem, 5, 139-147. 29. Pereira, R.L.C., Ibrahim, T., Lucchetti, L., da Silva, A.J.R. and de Moraes, V.L.G. (1999) Immunosuppressive and anti-inflammatory effects of methanolic extract and the polyacetylene isolated from Bidens pilosa L. Immunopharmacology, 43, 31-37. 30. Lu, H.M., Liang, Y.Z., Yi, L.Z. and Wu, X.J. (2006) Anti-inflammatory effect of Houttuynia cordata injection. Journal of ethnopharmacology, 104, 245-249. 31. Lu, H.M., Liang, Y.Z. and Chen, S. (2006) Identification and quality assessment of Houttuynia cordata injection using GC-MS fingerprint: A standardization approach. Journal of ethnopharmacology, 105, 436-440. 32. Ji, K.M., Chen, J.J., Li, M., Liu, Z.G., Xia, L.X., Wang, C.B., Zhan, Z.K. and Wu, X.L. (2009) Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections. Regul Toxicol Pharm, 55, 134-138. 33. Li, W.F., Zhou, P., Zhang, Y.M. and He, L.C. (2011) Houttuynia cordata, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Journal of ethnopharmacology, 133, 922-927. 34. Lai, K.C., Chiu, Y.J., Tang, Y.J., Lin, K.L., Chiang, J.H., Jiang, Y.L., Jen, H.F., Kuo, Y.H., Agamaya, S., Chung, J.G. et al. (2010) Houttuynia cordata Thunb Extract Inhibits Cell Growth and Induces Apoptosis in Human Primary Colorectal Cancer Cells. Anticancer research, 30, 3549-3556. 35. Tang, Y.J., Yang, J.S., Lin, C.F., Shyu, W.C., Tsuzuki, M., Lu, C.C., Chen, Y.F. and Lai, K.C. (2009) Houttuynia cordata Thunb extract induces apoptosis through mitochondrial-dependent pathway in HT-29 human colon adenocarcinoma cells. Oncology reports, 22, 1051-1056. 36. Yarden, Y. and Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. Nature reviews. Molecular cell biology, 2, 127-137. 37. Herbst, R.S. (2004) Review of epidermal growth factor receptor biology. International journal of radiation oncology, biology, physics, 59, 21-26. 38. Herbst, R.S. and Langer, C.J. (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars in oncology, 29, 27-36. 39. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182. 40. Ethier, S.P. (2002) Signal transduction pathways: the molecular basis for targeted therapies. Seminars in radiation oncology, 12, 3-10. 41. Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A., Morrison, D.K., Kaplan, D.R. and Tsichlis, P.N. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81, 727-736. 42. Woodgett, J.R. (2005) Recent advances in the protein kinase B signaling pathway. Current opinion in cell biology, 17, 150-157. 43. Kim, D. and Chung, J. (2002) Akt: versatile mediator of cell survival and beyond. J Biochem Mol Biol, 35, 106-115. 44. Masferrer, J.L., Leahy, K.M., Koki, A.T., Zweifel, B.S., Settle, S.L., Woerner, B.M., Edwards, D.A., Flickinger, A.G., Moore, R.J. and Seibert, K. (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-1311. 45. Kim, D., Kim, S., Koh, H., Yoon, S.O., Chung, A.S., Cho, K.S. and Chung, J. (2001) Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J, 15, 1953-1962. 46. Wu, S.R., Cheng, T.S., Chen, W.C., Shyu, H.Y., Ko, C.J., Huang, H.P., Teng, C.H., Lin, C.H., Johnson, M.D., Lin, C.Y. et al. (2010) Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. The American journal of pathology, 177, 3145-3158. 47. Manske, M. and Bade, E.G. (1994) Growth factor-induced cell migration: biology and methods of analysis. International review of cytology, 155, 49-96. 48. LaMarca, H.L., Dash, P.R., Vishnuthevan, K., Harvey, E., Sullivan, D.E., Morris, C.A. and Whitley, G.S.J. (2008) Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases. Hum Reprod, 23, 1733-1741. 49. Faivre, S., Kroemer, G. and Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents. Nature reviews. Drug discovery, 5, 671-688. 50. Vivanco, I. and Sawyers, C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews. Cancer, 2, 489-501. 51. Larsen, M., Tremblay, M.L. and Yamada, K.M. (2003) Phosphatases in cell-matrix adhesion and migration. Nature reviews. Molecular cell biology, 4, 700-711. 52. Ridley, A.J. and Hall, A. (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell, 70, 389-399. 53. Ridley, A.J., Paterson, H.F., Johnston, C.L., Diekmann, D. and Hall, A. (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell, 70, 401-410. 54. Kozma, R., Ahmed, S., Best, A. and Lim, L. (1995) The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Molecular and cellular biology, 15, 1942-1952. 55. Mitra, S.K., Hanson, D.A. and Schlaepfer, D.D. (2005) Focal adhesion kinase: in command and control of cell motility. Nature reviews. Molecular cell biology, 6, 56-68. 56. Cairns, R.A., Khokha, R. and Hill, R.P. (2003) Molecular mechanisms of tumor invasion and metastasis: an integrated view. Current molecular medicine, 3, 659-671. 57. Sternlicht, M.D. and Werb, Z. (2001) How matrix metalloproteinases regulate cell behavior. Annual review of cell and developmental biology, 17, 463-516. 58. Egeblad, M. and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature reviews. Cancer, 2, 161-174. 59. Lynch, C.C. and Matrisian, L.M. (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation; research in biological diversity, 70, 561-573. 60. Fingleton, B. (2006) Matrix metalloproteinases: roles in cancer and metastasis. Frontiers in bioscience : a journal and virtual library, 11, 479-491. 61. Liotta, L.A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C.M. and Shafie, S. (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-68. 62. Liotta, L.A. (1986) Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res, 46, 1-7. 63. Devarajan, P., Johnston, J.J., Ginsberg, S.S., Van Wart, H.E. and Berliner, N. (1992) Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells. J Biol Chem, 267, 25228-25232. 64. Howard, E.W. and Banda, M.J. (1991) Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J Biol Chem, 266, 17972-17977. 65. Strongin, A.Y., Collier, I., Bannikov, G., Marmer, B.L., Grant, G.A. and Goldberg, G.I. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem, 270, 5331-5338. 66. Kinoshita, T., Sato, H., Okada, A., Ohuchi, E., Imai, K., Okada, Y. and Seiki, M. (1998) TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem, 273, 16098-16103. 67. Butler, G.S., Butler, M.J., Atkinson, S.J., Will, H., Tamura, T., Schade van Westrum, S., Crabbe, T., Clements, J., d'Ortho, M.P. and Murphy, G. (1998) The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem, 273, 871-880. 68. Zucker, T.P., Bonisch, D., Muck, S., Weber, A.A., Bretschneider, E., Glusa, E. and Schror, K. (1998) Thrombin-induced mitogenesis in coronary artery smooth muscle cells is potentiated by thromboxane A2 and involves upregulation of thromboxane receptor mRNA. Circulation, 97, 589-595. 69. Hernandez-Barrantes, S., Toth, M., Bernardo, M.M., Yurkova, M., Gervasi, D.C., Raz, Y., Sang, Q.A. and Fridman, R. (2000) Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem, 275, 12080-12089. 70. Michaluk, P. and Kaczmarek, L. (2007) Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ, 14, 1255-1258. 71. Olson, M.W., Gervasi, D.C., Mobashery, S. and Fridman, R. (1997) Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem, 272, 29975-29983. 72. Balkwill, F.R. (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer - Reply. Cancer Res, 56, 3610-3610. 73. Westermarck, J. and Kahari, V.M. (1999) Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J, 13, 781-792. 74. Mendes, O., Kim, H.T. and Stoica, G. (2005) Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis, 22, 237-246. 75. Deryugina, E.I. and Quigley, J.P. (2006) Matrix metalloproteinases and tumor metastasis. Cancer metastasis reviews, 25, 9-34. 76. Cravatt, B.F., Wright, A.T. and Kozarich, J.W. (2008) Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annual review of biochemistry, 77, 383-414. 77. Liu, Y., Patricelli, M.P. and Cravatt, B.F. (1999) Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci U S A, 96, 14694-14699. 78. Evans, M.J. and Cravatt, B.F. (2006) Mechanism-based profiling of enzyme families. Chemical reviews, 106, 3279-3301. 79. Giard, D.J., Aaronson, S.A., Todaro, G.J., Arnstein, P., Kersey, J.H., Dosik, H. and Parks, W.P. (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. Journal of the National Cancer Institute, 51, 1417-1423. 80. Kaighn, M.E., Narayan, K.S., Ohnuki, Y., Lechner, J.F. and Jones, L.W. (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investigative urology, 17, 16-23. 81. Sramkoski, R.M., Pretlow, T.G., 2nd, Giaconia, J.M., Pretlow, T.P., Schwartz, S., Sy, M.S., Marengo, S.R., Rhim, J.S., Zhang, D. and Jacobberger, J.W. (1999) A new human prostate carcinoma cell line, 22Rv1. In vitro cellular & developmental biology. Animal, 35, 403-409. 82. Walker-Nasir, E., Codington, J.F., Jahnke, M.R., Fuller, T.C. and Jeanloz, R.W. (1982) Isolation and partial characterization of surface components of cell line MDA-MB-231 derived from a human metastatic breast carcinoma. Journal of the National Cancer Institute, 69, 371-380. 83. Morikawa, K., Walker, S.M., Jessup, J.M. and Fidler, I.J. (1988) In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res, 48, 1943-1948. 84. Morikawa, K., Walker, S.M., Nakajima, M., Pathak, S., Jessup, J.M. and Fidler, I.J. (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res, 48, 6863-6871. 85. Kim, S.K., Ryu, S.Y., No, J., Choi, S.U. and Kim, Y.S. (2001) Cytotoxic alkaloids from Houttuynia cordata. Archives of pharmacal research, 24, 518-521. 86. Chen, Y.Y., Liu, J.F., Chen, C.M., Chao, P.Y. and Chang, T.J. (2003) A study of the antioxidative and antimutagenic effects of Houttuynia cordata Thunb. Using an oxidized frying oil-fed model. Journal of nutritional science and vitaminology, 49, 327-333. 87. Lin, T.Y., Liu, Y.C., Jheng, J.R., Tsai, H.P., Jan, J.T., Wong, W.R. and Horng, J.T. (2009) Anti-Enterovirus 71 Activity Screening of Chinese Herbs with Anti-Infection and Inflammation Activities. Am J Chinese Med, 37, 143-158. 88. Berthon, P., Cussenot, O., Hopwood, L., Leduc, A. and Maitland, N. (1995) Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells - differentiation pattern of nontumorigenic cell-lines. International journal of oncology, 6, 333-343. 89. Whitfield, M.L., George, L.K., Grant, G.D. and Perou, C.M. (2006) Common markers of proliferation. Nature reviews. Cancer, 6, 99-106. 90. Acosta, J.C. and Gil, J. (2012) Senescence: a new weapon for cancer therapy. Trends in cell biology, 22, 211-219. 91. Desch, A., Strozyk, E.A., Bauer, A.T., Huck, V., Niemeyer, V., Wieland, T. and Schneider, S.W. (2012) Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin alphavbeta5-induced secretion of VEGF-A. The American journal of pathology, 181, 693-705. 92. Seiki, M. (2002) The cell surface: the stage for matrix metalloproteinase regulation of migration. Current opinion in cell biology, 14, 624-632. 93. Yuan, R. and Lin, Y. (2000) Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacology & therapeutics, 86, 191-198. 94. Tsai, C.H., Lin, F.M., Yang, Y.C., Lee, M.T., Cha, T.L., Wu, G.J., Hsieh, S.C. and Hsiao, P.W. (2009) Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res, 15, 5435-5444. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60965 | - |
dc.description.abstract | 癌症在台灣及許多國家都是主要死因之一。雖然對於癌症治療的相關研究不斷在進行,直至今日仍尚未出現對轉移性癌症具效用的療法。針對轉移性癌症,化學治療是普遍常用的方式之一,但也常伴隨著副作用,如疲勞、噁心、嘔吐並且造成病患身體虛弱。因此針對此癌症開發具療效且低毒性的新藥物,有迫切性的需要。天然植物萃取物一般具低毒性且被使用於保健及草藥方面已有一段很長的時間。因此從天然植物萃取物找出有效成份作為治療癌症的輔助療法或者替代療法,是一種相當可行的方式。在台灣及中國,HC草藥常廣泛地被運用於抗病毒、抗菌、抗發炎及對抗癌症等方面。雖HC已被使用於抑制癌症病程,但其有效成分尚不清楚。在本篇研究中,我想釐清HC萃取物是否可抑制癌細胞的移動及侵襲能力,並且探討HC抑制癌細胞移動侵襲力的作用機制。與中研院農生中心蕭培文老師及生物技術開發中心賴宗賢、錢瑤珍老師合作,HC酒精萃取物經高效能液相層析法分離出不同部分。我的結果發現八號分離層(HC-8)能夠有效地抑制多種癌細胞的移動侵襲能力。這些癌細胞包括肺癌細胞(A549)、乳癌細胞(MDA-MB-231)、前列腺癌細胞(PC-3和CWR22Rv1)以及大腸癌細胞(KM12-SM)。有趣的是對正常前列腺表皮細胞(PNT2),HC-8較不具影響力。在A549及PC-3細胞中,發現HC-8抑制癌細胞移動力,部份的原因是透過降低FAK、PDK1、AKT和mTOR的磷酸化,以及EGFR、HER2和mTOR蛋白質的量。另外經明膠酶譜法分析,發現HC-8可抑制A549和PC-3細胞分泌基質金屬蛋白酶二號(MMP2)及九號(MMP9)至胞外,進而降低其活性。總結以上的結果,HC-8能夠透過抑制EGFR、HER2、FAK、PDK1、AKT及細胞外MMP蛋白酶活性,進而有效地抑制癌細胞的侵襲移動能力。 | zh_TW |
dc.description.abstract | Cancer has been the leading cause of death in Taiwan and around the world. Although many research works are trying hard to identify useful compounds or approaches for cancer therapy, there is currently no effective way to cure advanced human cancer. Chemotherapy is often used to treat cancer patients, but most chemotherapy has severe side effects and makes the patients painful and weakening. Therefore, to identify a new drug or compound with low toxicity and high efficacy is imperative for cancer therapy. Since botanical extracts or compounds contained in herbal medicine have been used for a long time and exhibit low toxicity, among them, HC herb has been wildly used in Taiwan and China as a medicine for antivirus, antibacteria, anti-cancer and anti-inflammation. Thus, in this study, I would like to identify whether HC herb ethanol extract have effective ingredients to inhibit human cancer cell migration and invasion, as well as what molecular mechanisms were affected by the effective HC extract. To isolate the effective fractions of HC, with collaborations with Drs. Pei-Wen Hsiao, Tzung-Hsein Lai and Yau-Jan Chyan, dry HC was used for ethanol extraction and the HC extracts were fractioned by HPLC. With cell migration and invasion assays, the results showed that the fraction 8 (HC-8) could effectually inhibit several cancer cell invasion and migration, including lung cancer (A549), breast cancer (MDA-MB-231), prostate cancer (PC-3, CW22Rv1) and colon cancer (KM12-SM) cells. Interestingly, HC-8 had no significant effect on the motility of normal prostate epithelial PNT2cells. Moreover, HC-8 to inhibit A549 and PC-3 cell motility was at least in part due to its effect on reducing the protein levels of EGFR, HER2 and mTOR, or the phosphorylation levels of FAK, PDK1, and AKT. In addition, we also found that HC-8 was able to reduce the zymographic activity of MMP2/9 by reducing the protease secretion in A549 and PC-3 cells. In conclusion, HC-8 can inhibit the migration and invasion of human cancer cells, at least partly due to their inhibitory effects on EGFR, HER2, FAK, PDK1 and AKT, as well as suppression of MMP proteolytic activity. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T10:38:50Z (GMT). No. of bitstreams: 1 ntu-102-R00442027-1.pdf: 5762274 bytes, checksum: f2a17dc67970dff0a19b6cc485c654dd (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 致謝…………………………………………………………………………………………………I
摘要……………………………………………………………………………………….…………II Abstract……………………………………………………………………………………….…….III Chapter 1. Introduction 1 1.1 Cancer progression and metastasis 2 1.2 HC 5 1.3 Signaling pathway 5 1.4 Matrix metalloproteinase (MMP) 7 1.5 Activity-based protein profiling (ABPP) 8 1.6 Research motivation 9 Chapter 2. Materials and Methods 10 2.1 Materials 11 2.2 Methods 17 Chapter 3. Results 25 3.1 Effect of whole HC ethanol extract on A549 and PC-3 cell migration and viability. 26 3.2 Effect of different HC fractions on various cancer cell invasion and migration. 26 3.3 Cell viability of HC-8 and HC-9 in A549, MDA-MB-231, PC-3, CWR22Rv1 and KM12-SM cells. 28 3.4 Effect of HC-8 on PC-3 and PNT2 cell invasion. 29 3.5 Effect of the whole HC ethanol extract, HC-8 and HC-9 on the growth of A549 and PC-3 cells. 29 3.6 Effect of HC-8 on the protein or phosphorylation levels of several signal molecules related to the EGFR, HER2 and FAK pathways in A549 and PC-3 cells. 30 3.7 Effect of HC-8 on the gelatinolytic activity, expression and secretion of MMP2/9 in A549 and PC-3 cells. 32 3.8 Identification of serine hydrolyases affected by HC-8, using an activity-based probe in A549 and PC-3 cells. 33 Chatper 4. Discussion 34 Chapter 5. Figures 38 Chapter 6. References 64 | |
dc.language.iso | en | |
dc.title | HC萃取物對癌細胞轉移及侵襲能力之影響 | zh_TW |
dc.title | Effect of HC Extracts on Cancer Cell Motility and Invasion | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林榮耀,蕭培文,賴宗賢 | |
dc.subject.keyword | 中草藥,癌症,轉移,蛋白酶, | zh_TW |
dc.subject.keyword | cancer,invasion,migration,metastasis and MMP, | en |
dc.relation.page | 71 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 5.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。